search
Back to results

ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

Primary Purpose

T-cell Large Granular Lymphocytic Leukemia

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
ABC008
Sponsored by
Abcuro, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for T-cell Large Granular Lymphocytic Leukemia focused on measuring T-cell Large Granular Lymphocytic Leukemia, T-LGLL

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Is at least 18 years of age.
  • Has body mass index (BMI) ≤35 kg/m2.
  • Has a documented diagnosis of T LGLL.
  • Has any 1 or more of the following at Screening:

    • Absolute neutrophil count (ANC) <0.5 x 109/L
    • ANC ≥0.5 x 109/L and <1.0 x 109/L associated with recurrent infection (≥2 or more infections requiring antimicrobial therapy within the previous 12 months)
    • Hgb <8 g/dL or packed red blood cell transfusion frequency ≥1 time in the 4 weeks immediately prior to Screening
    • Hgb ≥8 g/dL and <10 g/dL accompanied by documented symptoms of anemia, e.g., fatigue, weakness, pale or yellowish skin, irregular heartbeat, shortness of breath, dizziness, or lightheadedness.
  • Has adequate hepatic and renal function at Screening, as indicated by:

    • Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST); <2.5x the upper limit of normal (ULN)
    • Total bilirubin ≤1.5 ULN
    • Estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation corrected for the body surface area of the subject calculated by the Mosteller equation and divided by 1.73
  • Agrees to adhere to the current Centers for Disease Control advice regarding minimizing exposure to severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) from the first Screening Visit until the End of Study (EOS)/Early Termination Visit (ETV).

Exclusion Criteria:

  • Has reactive large granular lymphocytosis.
  • Has active anemia secondary to confirmed etiologies other than T-LGLL, including known vitamin or mineral deficiency, gastrointestinal bleeding, or genetic disorder; or has active neutropenia secondary to known vitamin or mineral deficiencies or genetic disorder.
  • Has a platelet count ≤20 x 109/L or other clinically significantly abnormal laboratory results not related to the underlying condition in the Investigator's or Sponsor's opinion at Screening.
  • Has known hypersensitivity to any component of the formulation of ABC008, or history of anaphylaxis to any prior mAb therapy.
  • Has received more than 3 immunosuppressant therapies/chemotherapeutic agents (except for prednisone/prednisone equivalent) for the treatment of T LGLL.
  • Has any other autoimmune or autoinflammatory disease other than RA, inclusion body myositis (IBM), secondary Sjogren's syndrome (SS), or thyroid disease.
  • Has another myelo /lympho proliferative disorder or malignancy (other than monoclonal gammopathy of unknown significance [MGUS] not requiring treatment) within the past 5 years prior to Screening except completely resected nonmelanoma skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ at any site.
  • Has a current diagnosis of active tuberculosis (TB)
  • Has a history of herpes zoster infection that was disseminated, required hospitalization, or IV antiviral therapy in the 24 weeks prior to Day 1.
  • Active, chronic, or past history of hepatitis B virus or hepatitis C virus (HCV) infection (hepatitis B core antibody or surface antigen positive, or HCV antibody positive with reflex HCV ribonucleic acid [RNA] positive at Screening; individuals who have received curative therapy for HCV are permitted if therapy was completed at least 24 weeks prior to Screening and subject is HCV RNA negative);
  • Has known active bacterial, viral, fungal, or atypical mycobacterial infection, or any major episode of infection that required hospitalization
  • Has received live (including attenuated) vaccination in the 30 days prior to Day 1 or killed vaccine within 14 days prior to Day 1.
  • Is human immunodeficiency virus (HIV) positive by antigen/antibody test, human T cell lymphotropic virus (HTLV 1 or 2) positive by antibody test.
  • Has had major surgery (defined as surgery requiring general or regional anesthesia) within 6 weeks prior to Day 1 or is expected to receive surgery during the study.
  • Has a history of organ transplant (e.g., solid, bone marrow) or is expected to receive one during the study.
  • Has any other condition or social situations that would interfere with the subject's study participation, increase the risk associated with study participation or investigational product administration, interfere with the interpretation of study results, or would otherwise make the subject inappropriate for entry into this study in the Investigator's or Sponsor's opinion.

Sites / Locations

  • City of HopeRecruiting
  • University of Southern CaliforniaRecruiting
  • Massachusetts General HospitalRecruiting
  • Dana-Farber Cancer InstituteRecruiting
  • SUNY Upstate Medical UniversityRecruiting
  • Cleveland Clinic FoundationRecruiting
  • The University of Texas M.D. Anderson Cancer CenterRecruiting
  • Huntsman Cancer Institute, University of UtahRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

ABC008 Dose Level 1 Cohort

ABC008 Dose Level 2 Cohort

ABC008 Dose Level 3 Cohort

ABC008 Dose Level 4 Cohort

ABC008 Dose Level 5 Cohort

Arm Description

0.25 mg / kg ABC008 Subjects receive ABC008 every 8 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.

0.75 mg / kg ABC008 Subjects receive ABC008 every 8 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.

1.5 mg / kg ABC008 Subjects receive ABC008 every 8 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.

3.0 mg / kg ABC008 Subjects receive ABC008 every 8 weeks OR 1.5 mg / kg Subjects receive ABC008 every 4 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.

3.0 mg / kg ABC008 Subjects receive ABC008 every 4 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.

Outcomes

Primary Outcome Measures

Incidence, nature, and severity of treatment-emergent AEs and SAEs as determined by NCI CTCAE v5.0

Secondary Outcome Measures

Change from baseline in safety lab (Hematology)
Change from baseline in safety lab (Chemistry)
Change from baseline in safety lab (Coagulation)
Includes the following coagulation labs: INR and aPTT
Change from baseline in safety lab (Complement)
Includes the following complement labs: C3 and CH50
Change from baseline in safety lab (Cytokines)
Change from baseline in safety lab (CMV Viral Load)
Change from baseline in safety lab (EBV Viral Load)
Change from baseline in ECG (Rhythm)
Change from baseline in ECG (Heart Rate)
Change from baseline in ECG parameters
Includes the following ECG parameters: RR interval, PR interval, QRS interval, QT interval, QT interval corrected by Bazett's formula, and QTcF
Change from baseline in vital sign (Systolic and diastolic blood pressure)
Change from baseline in vital sign (temperature)
Change from baseline in vital sign (respiratory rate)
Change from baseline in vital sign (pulse rate)
Percentage of subjects demonstrating overall response (defined as total number of subjects with CR or PR) at all time points assessed
Percentage of subjects demonstrating complete response at all time points assessed
A complete response is defined by normalization of hemoglobin, neutrophil and platelet levels without transfusion
Percentage of subjects demonstrating partial response at all time points assessed
A partial response is defined by improvement in any of the following criteria but not all: hemoglobin, neutrophil and platelet levels without transfusion
Duration of response at all time points assessed
Overall survival at Week 48
The change from baseline in levels of KLRG1 expressing lymphocytes over time
The change from baseline in levels of T-LGL counts over time
The change from baseline in levels of lymphocyte subsets over time
The maximum serum concentration [CMax] of ABC008
The time to maximum concentration [TMax] of ABC008
The area under the concentration-time curve [AUC] of ABC008
The apparent clearance [CL/F] of ABC008
The apparent volume of distribution [Vd/F] of ABC008
The elimination half-life [t½] of ABC008

Full Information

First Posted
August 19, 2022
Last Updated
September 22, 2023
Sponsor
Abcuro, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05532722
Brief Title
ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Official Title
A Study of ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 28, 2022 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abcuro, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
T-cell Large Granular Lymphocytic Leukemia
Keywords
T-cell Large Granular Lymphocytic Leukemia, T-LGLL

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ABC008 Dose Level 1 Cohort
Arm Type
Experimental
Arm Description
0.25 mg / kg ABC008 Subjects receive ABC008 every 8 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.
Arm Title
ABC008 Dose Level 2 Cohort
Arm Type
Experimental
Arm Description
0.75 mg / kg ABC008 Subjects receive ABC008 every 8 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.
Arm Title
ABC008 Dose Level 3 Cohort
Arm Type
Experimental
Arm Description
1.5 mg / kg ABC008 Subjects receive ABC008 every 8 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.
Arm Title
ABC008 Dose Level 4 Cohort
Arm Type
Experimental
Arm Description
3.0 mg / kg ABC008 Subjects receive ABC008 every 8 weeks OR 1.5 mg / kg Subjects receive ABC008 every 4 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.
Arm Title
ABC008 Dose Level 5 Cohort
Arm Type
Experimental
Arm Description
3.0 mg / kg ABC008 Subjects receive ABC008 every 4 weeks. Cohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.
Intervention Type
Drug
Intervention Name(s)
ABC008
Intervention Description
Given subcutaneous injection
Primary Outcome Measure Information:
Title
Incidence, nature, and severity of treatment-emergent AEs and SAEs as determined by NCI CTCAE v5.0
Time Frame
Through Study Completion an average of 48 weeks
Secondary Outcome Measure Information:
Title
Change from baseline in safety lab (Hematology)
Time Frame
Through Study Completion an average of 48 weeks
Title
Change from baseline in safety lab (Chemistry)
Time Frame
Through Study Completion an average of 48 weeks
Title
Change from baseline in safety lab (Coagulation)
Description
Includes the following coagulation labs: INR and aPTT
Time Frame
Through Study Completion an average of 48 weeks
Title
Change from baseline in safety lab (Complement)
Description
Includes the following complement labs: C3 and CH50
Time Frame
Through Study Completion an average of 48 weeks
Title
Change from baseline in safety lab (Cytokines)
Time Frame
Through Study Completion an average of 48 weeks
Title
Change from baseline in safety lab (CMV Viral Load)
Time Frame
Through Study Completion an average of 48 weeks
Title
Change from baseline in safety lab (EBV Viral Load)
Time Frame
Through Study Completion an average of 48 weeks
Title
Change from baseline in ECG (Rhythm)
Time Frame
Through Study Completion an average of 48 weeks
Title
Change from baseline in ECG (Heart Rate)
Time Frame
Through Study Completion an average of 48 weeks
Title
Change from baseline in ECG parameters
Description
Includes the following ECG parameters: RR interval, PR interval, QRS interval, QT interval, QT interval corrected by Bazett's formula, and QTcF
Time Frame
Through Study Completion an average of 48 weeks
Title
Change from baseline in vital sign (Systolic and diastolic blood pressure)
Time Frame
Through Study Completion an average of 48 weeks
Title
Change from baseline in vital sign (temperature)
Time Frame
Through Study Completion an average of 48 weeks
Title
Change from baseline in vital sign (respiratory rate)
Time Frame
Through Study Completion an average of 48 weeks
Title
Change from baseline in vital sign (pulse rate)
Time Frame
Through Study Completion an average of 48 weeks
Title
Percentage of subjects demonstrating overall response (defined as total number of subjects with CR or PR) at all time points assessed
Time Frame
Day 1 and throughout the 48 weeks of follow up
Title
Percentage of subjects demonstrating complete response at all time points assessed
Description
A complete response is defined by normalization of hemoglobin, neutrophil and platelet levels without transfusion
Time Frame
Day 1 and throughout the 48 weeks of follow up
Title
Percentage of subjects demonstrating partial response at all time points assessed
Description
A partial response is defined by improvement in any of the following criteria but not all: hemoglobin, neutrophil and platelet levels without transfusion
Time Frame
Day 1 and throughout the 48 weeks of follow up
Title
Duration of response at all time points assessed
Time Frame
Day 1 and throughout the 48 weeks of follow up
Title
Overall survival at Week 48
Time Frame
Day 1 and throughout the 48 weeks of follow up
Title
The change from baseline in levels of KLRG1 expressing lymphocytes over time
Time Frame
Day 1 and throughout the 48 weeks of follow up
Title
The change from baseline in levels of T-LGL counts over time
Time Frame
Day 1 and throughout the 48 weeks of follow up
Title
The change from baseline in levels of lymphocyte subsets over time
Time Frame
Day 1 and throughout the 48 weeks of follow up
Title
The maximum serum concentration [CMax] of ABC008
Time Frame
Day 1 and throughout the 48 weeks of follow up
Title
The time to maximum concentration [TMax] of ABC008
Time Frame
Day 1 and throughout the 48 weeks of follow up
Title
The area under the concentration-time curve [AUC] of ABC008
Time Frame
Day 1 and throughout the 48 weeks of follow up
Title
The apparent clearance [CL/F] of ABC008
Time Frame
Day 1 and throughout the 48 weeks of follow up
Title
The apparent volume of distribution [Vd/F] of ABC008
Time Frame
Day 1 and throughout the 48 weeks of follow up
Title
The elimination half-life [t½] of ABC008
Time Frame
Day 1 and throughout the 48 weeks of follow up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Is at least 18 years of age. Has body mass index (BMI) ≤35 kg/m2. Has a documented diagnosis of T LGLL. Has any 1 or more of the following at Screening: Absolute neutrophil count (ANC) <0.5 x 109/L ANC ≥0.5 x 109/L and <1.0 x 109/L associated with recurrent infection (≥2 or more infections requiring antimicrobial therapy within the previous 12 months) Hemoglobin (Hgb) <8 g/dL or packed red blood cell transfusion frequency ≥1 time in the 4 weeks immediately prior to Screening Hgb ≥8 g/dL and <10 g/dL accompanied by documented symptoms of anemia, e.g., fatigue, weakness, pale or yellowish skin, irregular heartbeat, shortness of breath, dizziness, or lightheadedness. Has adequate hepatic and renal function at Screening, as indicated by: Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST); <2.5x the upper limit of normal (ULN) Total bilirubin ≤1.5 ULN; subjects with Gilbert syndrome must have a total bilirubin <3.0x ULN with direct bilirubin <1.0x ULN at time of Screening Estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation corrected for the body surface area of the subject calculated by the Mosteller equation and divided by 1.73 Agrees to adhere to the current Centers for Disease Control advice regarding minimizing exposure to severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) from the first Screening Visit until the End of Study (EOS)/Early Termination Visit (ETV). Exclusion Criteria: Has reactive large granular lymphocytosis. Has active anemia secondary to confirmed etiologies other than T-LGLL, including known vitamin or mineral deficiency, gastrointestinal bleeding, or genetic disorder; or has active neutropenia secondary to known vitamin or mineral deficiencies or genetic disorder. Has a platelet count ≤20 x 109/L or other clinically significantly abnormal laboratory results not related to the underlying condition in the Investigator's or Sponsor's opinion at Screening. Has known hypersensitivity to any component of the formulation of ABC008, or history of anaphylaxis to any prior mAb therapy. Has any other autoimmune or autoinflammatory disease other than RA, inclusion body myositis (IBM), secondary Sjogren's syndrome (SS), or thyroid disease. Has another myelo /lympho proliferative disorder or malignancy (other than monoclonal gammopathy of unknown significance [MGUS] not requiring treatment) within the past 5 years prior to Screening except completely resected nonmelanoma skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ at any site. Has a current diagnosis of active tuberculosis (TB) Has a history of herpes zoster infection that was disseminated, required hospitalization, or IV antiviral therapy in the 24 weeks prior to Day 1. Active, chronic, or past history of hepatitis B virus or hepatitis C virus (HCV) infection (hepatitis B core antibody or surface antigen positive, or HCV antibody positive with reflex HCV ribonucleic acid [RNA] positive at Screening; individuals who have received curative therapy for HCV are permitted if therapy was completed at least 24 weeks prior to Screening and subject is HCV RNA negative); Has known active bacterial, viral, fungal, or atypical mycobacterial infection, or any major episode of infection that required hospitalization Has received live (including attenuated) vaccination in the 30 days prior to Day 1 or killed vaccine within 14 days prior to Day 1. Is human immunodeficiency virus (HIV) positive by antigen/antibody test, human T cell lymphotropic virus (HTLV 1 or 2) positive by antibody test. Has had major surgery (defined as surgery requiring general or regional anesthesia) within 6 weeks prior to Day 1 or is expected to receive surgery during the study. Has a history of organ transplant (e.g., solid, bone marrow) or is expected to receive one during the study. Has any other condition or social situations that would interfere with the subject's study participation, increase the risk associated with study participation or investigational product administration, interfere with the interpretation of study results, or would otherwise make the subject inappropriate for entry into this study in the Investigator's or Sponsor's opinion.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michael McClain
Phone
617-865-5078
Email
LGL-101_ClinicalTrial@abcuro.com
Facility Information:
Facility Name
City of Hope
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ryotaro Nakamura, M.D.
Phone
877-467-3411
First Name & Middle Initial & Last Name & Degree
Ryotaro Nakamura, M.D.
Facility Name
University of Southern California
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christine Duran
Email
duran_c@med.usc.edu
First Name & Middle Initial & Last Name & Degree
Howard Liebman, M.D.
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Salvia Jain
Phone
617-724-4000
First Name & Middle Initial & Last Name & Degree
Salvia Jain, M.D.
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
DFCI Clinical Trial Hotline
Phone
877-338-7425
First Name & Middle Initial & Last Name & Degree
Eric Jacobsen, M.D.
Facility Name
SUNY Upstate Medical University
City
Syracuse
State/Province
New York
ZIP/Postal Code
13210
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patricia Benz
Phone
315-464-8253
Email
benzp@upstate.edu
First Name & Middle Initial & Last Name & Degree
Bernard Poiesz, M.D.
Facility Name
Cleveland Clinic Foundation
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Moaath Mustafa Ali, M.D.
Phone
866-223-8100
Email
taussigresearch@ccf.org
First Name & Middle Initial & Last Name & Degree
Moaath Mustafa Ali, M.D.
Facility Name
The University of Texas M.D. Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tapan Kadia, M.D.
Phone
713-563-3435
Email
tkadia@mdanderson.org
First Name & Middle Initial & Last Name & Degree
Tapan Kadia, M.D.
Facility Name
Huntsman Cancer Institute, University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84112
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David L Samuel
Phone
801-587-9834
Email
David.Samuel@hci.utah.edu
First Name & Middle Initial & Last Name & Degree
Paul J Shami, M.D.

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

We'll reach out to this number within 24 hrs